Pfizer Inc. (PFE) research: valuation against peers, fundamentals over time, risk and news coverage
ChartVs peersValuationValue mapQuartersScaleMarginsTrajectoryCash qualityPer shareReinvestmentBalance sheetStreetRiskSeasonalityOur coverage
PFE
Pfizer Inc.USD
28.00
+1.82% today
Market cap
—
P/E trailing
—
P/E forward
—
EV/EBITDA
—
Op margin
—
Rev growth
—
Div yield
—
Beta
—
Price navigator — PFE
No data in this window.
What PFE trades with
The themes this instrument belongs to, and the rest of what sits inside them — the peer set a screener gives you is statistical, this one is editorial.
Obesity drugs & pharma
The GLP-1 duopoly, the challengers, and the sector they have been carrying.
INDY NEWS coverage of PFE1
Every report in our own archive tagged with this symbol, newest first — fetched from the archive alongside the market data.
- SPECIAL REPORTNEUTRALTiger Global Trims Big Tech, Rotates Into SpaceX as Private Markets Absorb Capital
Tiger Global Management cut stakes across mega-cap technology holdings while establishing an allocation to SpaceX, a reallocation that mirrors broader institutional discomfort with public AI valuations and growing appetite for privately held frontier assets.
Every figure on this page is fetched and computed in your browser from free public sources — end-of-day prices and reported financials from Yahoo Finance's open endpoints, and our own archive for the coverage panel. Fundamental history on the free tier runs about four fiscal years and five quarters. Data is best-effort and unaudited; this is market research, not investment advice.
Guidance reliability · PFEmethodology·all companies
Guides conservatively — has come in above its own forecast in 3 of 6 forecasts.
n = 6 resolved forecasts · FY 2023 to FY 2025 · 2 still outstanding
Pattern
conservatively
6 resolved
Avg. signed deviation
−0.6%
outside its own range
Avg. vs midpoint
+0.4%
where in the range it lands
Avg. range width
6.1%
room it leaves itself
Above guidance3In line1Below guidance2
Next report expected 03 Nov 2026 (Q3 FY2026) — Estimated from the issuer's own filing history: FY2025Q3 results were released on 2025-11-04. source
The record — 39 forecasts, 8 scoredevery figure sourced
| Period | Measure | Guided | Issued | Reported | Landed | Deviation | Verdict | Sources |
|---|---|---|---|---|---|---|---|---|
| FY 2026revised | EPS (adj.) | $2.80–$3.00 | 2026-08-04 | — | — | — | PENDING | guidance |
| “Reaffirms full-year 2026 Adjusted(3) diluted EPS guidance(2) in a range of $2.80 to $3.00.” | ||||||||
| FY 2026revised | Revenue | $60.50–$62.50bn | 2026-08-04 | — | — | — | PENDING | guidance |
| “Raises full-year 2026 Revenue guidance(2) by $500 million at the midpoint to a range of $60.5 to $62.5 billion, from $59.5 to $62.5 billion previously.” | ||||||||
| FY 2026revised | EPS (adj.) | $2.80–$3.00 | 2026-06-18 | — | — | — | PENDING | guidance |
| “Adjusted Diluted EPS in a Range of $2.80 to $3.00” | ||||||||
| FY 2026revised | Revenue | $59.50–$62.50bn | 2026-06-18 | — | — | — | PENDING | guidance |
| “Revenues in a range of $59.5 to $62.5 billion” | ||||||||
| FY 2026revised | EPS (adj.) | $2.80–$3.00 | 2026-05-05 | — | — | — | PENDING | guidance |
| “Adjusted(4) Diluted EPS in a Range of $2.80 to $3.00” | ||||||||
| FY 2026revised | Revenue | $59.50–$62.50bn | 2026-05-05 | — | — | — | PENDING | guidance |
| “Revenues in a range of $59.5 to $62.5 billion” | ||||||||
| FY 2026revised | EPS (adj.) | $2.80–$3.00 | 2026-02-03 | — | — | — | PENDING | guidance |
| “Reaffirms full-year 2026 Revenue guidance in a range of $59.5 to $62.5 billion and Adjusted(3) diluted EPS guidance(1) in a range of $2.80 to $3.00.” | ||||||||
| FY 2026revised | Revenue | $59.50–$62.50bn | 2026-02-03 | — | — | — | PENDING | guidance |
| “Reaffirms full-year 2026 Revenue guidance in a range of $59.5 to $62.5 billion and Adjusted(3) diluted EPS guidance(1) in a range of $2.80 to $3.00.” | ||||||||
| FY 2026 | EPS (adj.) | $2.80–$3.00 | 2025-12-16 | — | — | — | PENDING | guidance |
| “Pfizer anticipates full-year 2026 Adjusted(1) diluted EPS to be in a range of $2.80 to $3.00.” | ||||||||
| FY 2026 | Revenue | $59.50–$62.50bn | 2025-12-16 | — | — | — | PENDING | guidance |
| “Pfizer anticipates full-year 2026 revenues to be in the range of $59.5 to $62.5 billion” | ||||||||
| FY 2025revised | EPS (adj.) | $3.00–$3.15 | 2025-12-16 | $3.22 | +2.3% | ABOVE | guidance · result | |
| “Adjusted(1) Diluted EPS $3.00 – $3.15” | ||||||||
| FY 2025revised | Revenue | $62.0bn | 2025-12-16 | $62.6bn | +0.4% | ABOVE | guidance · result | |
| “full-year 2025 revenue guidance(2) is revised to approximately $62.0 billion from the range of $61.0 to $64.0 billion previously” | ||||||||
| FY 2025revised | EPS (adj.) | $3.00–$3.15 | 2025-11-04 | $3.22 | +2.3% | ABOVE | guidance · result | |
| “Raises and narrows Adjusted(2) diluted EPS guidance(1) to a range of $3.00 to $3.15 from $2.90 to $3.10 previously.” | ||||||||
| FY 2025revised | Revenue | $61.00–$64.00bn | 2025-11-04 | $62.6bn | 0.0% | IN LINE | guidance · result | |
| “Reaffirms full-year 2025 Revenue guidance of $61.0 to $64.0 billion.” | ||||||||
| FY 2025revised | EPS (adj.) | $2.90–$3.10 | 2025-08-05 | $3.22 | +4.0% | ABOVE | guidance · result | |
| “Raises Full-Year 2025 Adjusted(2) Diluted EPS Guidance(1) by $0.10 to a Range of $2.90 to $3.10, which Absorbs a One-Time Impact of Approximately $0.20 Related to 3SBio Transaction” | ||||||||
| FY 2025revised | Revenue | $61.00–$64.00bn | 2025-08-05 | $62.6bn | 0.0% | IN LINE | guidance · result | |
| “Reaffirms Full-Year 2025 Revenue Guidance(1) in a Range of $61.0 to $64.0 Billion” | ||||||||
| FY 2025revised | EPS (adj.) | $2.80–$3.00 | 2025-04-29 | $3.22 | +7.6% | ABOVE | guidance · result | |
| “Adjusted(3) Diluted EPS in a Range of $2.80 to $3.00” | ||||||||
| FY 2025revised | Revenue | $61.00–$64.00bn | 2025-04-29 | $62.6bn | 0.0% | IN LINE | guidance · result | |
| “Revenues in a Range of $61.0 to $64.0 Billion” | ||||||||
| FY 2025revised | EPS (adj.) | $2.80–$3.00 | 2025-02-04 | $3.22 | +7.6% | ABOVE | guidance · result | |
| “Reaffirms All Components of Full-Year 2025 Financial Guidance(5), including Revenues in a Range of $61.0 to $64.0 Billion and Adjusted(3) Diluted EPS in a Range of $2.80 to $3.00” | ||||||||
| FY 2025revised | Revenue | $61.00–$64.00bn | 2025-02-04 | $62.6bn | 0.0% | IN LINE | guidance · result | |
| “Revenues $61.0 to $64.0 billion” | ||||||||
| FY 2025 | EPS (adj.) | $2.80–$3.00 | 2024-12-17 | $3.22 | +7.6% | ABOVE | guidance · result | |
| “Pfizer anticipates full-year 2025 Adjusted(2) diluted EPS to be in a range of $2.80 to $3.00, reflecting expected operational(3) growth of 10% to 18%, year-over-year, from the midpoint of our 2024 baseline guidance(4), which excludes 2024 non-recurring items(4).” | ||||||||
| FY 2025 | Revenue | $61.00–$64.00bn | 2024-12-17 | $62.6bn | 0.0% | IN LINE | guidance · result | |
| “Pfizer anticipates full-year 2025 revenues to be in the range of $61.0 to $64.0 billion, which includes the expectation of revenues from our COVID-19 products in 2025 being largely consistent with 2024 after excluding approximately $1.2 billion of non-recurring revenue for Paxlovid in 2024.” | ||||||||
| FY 2024revised | Revenue | $61.00–$64.00bn | 2024-12-17 | $63.6bn | 0.0% | IN LINE | guidance · result | |
| “Revenues ($ in billions) $61.0 – $64.0” | ||||||||
| FY 2024revised | EPS (adj.) | $2.75–$2.95 | 2024-10-29 | $3.11 | +5.6% | ABOVE | guidance · result | |
| “Pfizer raises full-year 2024 revenue guidance by $1.5 billion at the midpoint to a range of $61.0 to $64.0 billion and raises Adjusted(2) diluted EPS guidance by $0.30 at the midpoint to $2.75 to $2.95.” | ||||||||
| FY 2024revised | Revenue | $61.00–$64.00bn | 2024-10-29 | $63.6bn | 0.0% | IN LINE | guidance · result | |
| “Pfizer raises full-year 2024 revenue guidance by $1.5 billion at the midpoint to a range of $61.0 to $64.0 billion and raises Adjusted(2) diluted EPS guidance by $0.30 at the midpoint to $2.75 to $2.95.” | ||||||||
| FY 2024revised | EPS (adj.) | $2.45–$2.65 | 2024-07-30 | $3.11 | +18.0% | ABOVE | guidance · result | |
| “Raises Adjusted(2) Diluted EPS Guidance to a Range of $2.45 to $2.65” | ||||||||
| FY 2024revised | Revenue | $59.50–$62.50bn | 2024-07-30 | $63.6bn | +1.8% | ABOVE | guidance · result | |
| “Raises Full-Year 2024 Revenue Guidance(1) to a Range of $59.5 to $62.5 Billion” | ||||||||
| FY 2024revised | EPS (adj.) | $2.15–$2.35 | 2024-05-01 | $3.11 | +33.8% | ABOVE | guidance · result | |
| “Reaffirms Full-Year 2024 Revenue Guidance(6) of $58.5 to $61.5 Billion and Raises Adjusted(3) Diluted EPS Guidance to $2.15 to $2.35” | ||||||||
| FY 2024revised | Revenue | $58.50–$61.50bn | 2024-05-01 | $63.6bn | +3.5% | ABOVE | guidance · result | |
| “The company still expects full-year 2024 revenues to be in the range of $58.5 to $61.5 billion” | ||||||||
| FY 2024revised | EPS (adj.) | $2.05–$2.25 | 2024-01-30 | $3.11 | +40.0% | ABOVE | guidance · result | |
| “2024 Adjusted(3) diluted EPS is anticipated to be in a range of $2.05 to $2.25, which primarily reflects:” | ||||||||
| FY 2024revised | Revenue | $58.50–$61.50bn | 2024-01-30 | $63.6bn | +3.5% | ABOVE | guidance · result | |
| “Pfizer expects full-year 2024 revenues(2) to be in the range of $58.5 to $61.5 billion, which includes approximately $8 billion in anticipated revenues for Comirnaty(1) and Paxlovid (approximately $5 billion and $3 billion, respectively), approximately $3.1 billion in anticipated revenues from Seagen and approximately $1 billion related to the reclassification of Pfizer’s royalty income from Other (Income)/Deductions into the Revenue line.” | ||||||||
| FY 2024 | EPS (adj.) | $2.05–$2.25 | 2023-12-13 | $3.11 | +40.0% | ABOVE | guidance · result | |
| “2024 Adjusted(5) diluted EPS is anticipated to be in a range of $2.05 to $2.25, which primarily reflects expected operational(3) growth of 8%-10% in revenues, excluding Comirnaty(2) and Paxlovid, and including the impact of Seagen, as well as anticipated operating margin improvement from the company’s cost realignment activities, partially offset by an expected $0.40 dilutive impact related to the Seagen acquisition, which is predominantly driven by costs to finance the transaction.” | ||||||||
| FY 2024 | Revenue | $58.50–$61.50bn | 2023-12-13 | $63.6bn | +3.5% | ABOVE | guidance · result | |
| “Pfizer expects full-year 2024 revenues to be in the range of $58.5 to $61.5 billion, which includes approximately $8 billion in anticipated revenues for Comirnaty(2) and Paxlovid, approximately $3.1 billion in anticipated revenues from Seagen and approximately $1 billion related to the reclassification of Pfizer’s royalty income from Other (Income)/Deductions into the Revenue line.” | ||||||||
| FY 2023revised | EPS (adj.) | $1.45–$1.65 | 2023-10-31 | $1.84 | +12.3% | ABOVE | guidance · result | |
| “Reaffirms Full-Year 2023 Guidance(4) Provided on October 13, 2023, of Revenues of $58.0 to $61.0 Billion and Adjusted(3) Diluted EPS of $1.45 to $1.65, and Provides All Guidance Components” | ||||||||
| FY 2023revised | Revenue | $58.00–$61.00bn | 2023-10-31 | $58.5bn | 0.0% | IN LINE | guidance · result | |
| “Reaffirms Full-Year 2023 Guidance(4) Provided on October 13, 2023, of Revenues of $58.0 to $61.0 Billion and Adjusted(3) Diluted EPS of $1.45 to $1.65, and Provides All Guidance Components” | ||||||||
| FY 2023revised | EPS (adj.) | $1.45–$1.65 | 2023-10-13 | $1.84 | +12.3% | ABOVE | guidance · result | |
| “Due to the aforementioned items, the company now expects full-year 2023 Adjusted(2) diluted EPS to be in the range of $1.45 to $1.65 versus its original guidance range of $3.25 to $3.45.” | ||||||||
| FY 2023revised | Revenue | $58.00–$61.00bn | 2023-10-13 | $58.5bn | 0.0% | IN LINE | guidance · result | |
| “Pfizer also announced that it now anticipates full-year 2023 revenues to be in the range of $58.0 to $61.0 billion, versus its previous guidance range of $67.0 to $70.0 billion solely due to its COVID products.” | ||||||||
| FY 2023 | EPS (adj.) | $3.25–$3.45 | 2023-08-01 | $1.84 | −42.1% | BELOW | guidance · result | |
| “$3.25 to $3.45” | ||||||||
| FY 2023 | Revenue | $67.00–$70.00bn | 2023-08-01 | $58.5bn | −12.4% | BELOW | guidance · result | |
| “Revenues $67.0 to $70.0 billion (previously $67.0 to $71.0 billion)” | ||||||||
Every figure above is read from the company’s own filings. “Guidance” links to the 8-K exhibit that issued the forecast; “result” links to the exhibit in which the company reported the outcome. Nothing here is an analyst estimate. How this is measured.
Coverage universe: S&P 100. This is a factual record of what a company forecast and what it then reported. It is not investment advice, and it is not a view on the company’s prospects — we publish the measurement and draw no conclusion from it.